Screening for Prostate Cancer in Older Patients (PLCO Screening Trial) (NCT00002540) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)
United States76,685 participantsStarted 1993-11-16
Plain-language summary
This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for prostate cancer.
Who can participate
Age range55 Years – 74 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Exclusion Criteria:
* Men who at the time of randomization are less than 55 or greater than or equal to 75 years of age
* Individuals undergoing treatment for cancer at this time, excluding basal-cell and squamous-cell skin cancer
* Individuals with known prior cancer of the colon, rectum, lung, prostate
* This includes primary or metastatic PLCO cancers
* Individuals with previous surgical removal of the entire colon, one lung, or the entire prostate
* Individuals who are participating in another cancer screening or cancer primary prevention trial
* Males who have taken Proscar/Propecia/finasteride in the past 6 months
* NOTE: Individuals who are already enrolled in the trial when their physician prescribes finasteride are not prevented from taking this medication. As a result, these participants will continue to be screened and followed just as those participants who are not on finasteride.
* NOTE: Men who are taking Tamoxifen are not excluded from any part of the PLCO Screening Trial.
* Individuals who are unwilling or unable to sign the informed consent form
* Males who have had more than one PSA blood test in the past three years
* Individuals who have had a colonoscopy, sigmoidoscopy, or barium enema in the past three years
What they're measuring
1
Prostate Cancer Deaths
Timeframe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.
2
Prostate Cancer Death Rates
Timeframe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.